Hase H, Imamura Y, Nakamura R, Inishi Y, Machii K, Yamaguchi T
Third Department of Internal Medicine, Toho University Ohashi Hospital, Tokyo, Japan.
Jpn Circ J. 1993 Feb;57(2):131-7. doi: 10.1253/jcj.57.131.
We investigated the effects of recombinant human erythropoietin (rHuEPO) therapy on exercise capacity by symptom-limited maximal treadmill exercise testing in 9 patients with coronary artery disease who were receiving maintenance hemodialysis. The initial hemoglobin concentration of 7.9 +/- 0.7 g/dl, (mean +/- S.D.) rose to 10.4 +/- 1.1 g/dl, (p < 0.01) after three months of rHuEPO therapy. The partial correction of renal anemia resulted in a significant increase in exercise duration (from 278 +/- 84 sec to 384 +/- 74 sec, p < 0.01) and maximum pressure-rate product (from 228.3 +/- 50.3 mmHg.bpm/10(2) to 262.8 +/- 40.4 mmHg.bpm/10(2), p < 0.01). The maximum exercise-induced ST segment depression significantly decreased after treatment (from 1.3 +/- 0.5 mm to 0.5 +/- 0.5 mm, p < 0.05). These results suggest that the improvement in maximum coronary oxygen supply exceeded the increased maximum myocardial oxygen requirements after the partial correction of renal anemia by rHuEPO therapy in hemodialysis patients with coronary artery disease.
我们通过症状限制最大运动平板试验，研究了重组人促红细胞生成素（rHuEPO）治疗对9例接受维持性血液透析的冠心病患者运动能力的影响。rHuEPO治疗3个月后，初始血红蛋白浓度从7.9±0.7 g/dl（平均值±标准差）升至10.4±1.1 g/dl（p<0.01）。肾性贫血的部分纠正导致运动持续时间显著增加（从278±84秒增至384±74秒，p<0.01）以及最大压力-心率乘积显著增加（从228.3±50.3 mmHg·bpm/10²增至262.8±40.4 mmHg·bpm/10²，p<0.01）。治疗后最大运动诱发ST段压低显著降低（从1.3±0.5 mm降至0.5±0.5 mm，p<0.05）。这些结果表明，在接受rHuEPO治疗的冠心病血液透析患者中，肾性贫血部分纠正后，最大冠状动脉氧供的改善超过了最大心肌氧需求的增加。
